Seven Poster Abstracts Highlight MiMedx Allografts at the 10th Annual Desert Foot Conference STUDIES DEMONSTRATE STRONG HEALING RESULTS OF EPIFIX® AND AMNIOFIX® PR Newswire MARIETTA, Ga., Nov. 26, 2013 MARIETTA, Ga., Nov. 26, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the summaries of a selection of the seven posters highlighting MiMedx allografts presented at the recent 10^th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona. The posters chronicled the clinical effectiveness of the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts and detailed a wide range of wounds and injuries with varying degrees of etiologies. A sampling of the posters presenting dHACM cases and studies, along with a summary of the respective study results and conclusions are as follows: oEpiFix Utilization for Advanced Wound Therapy in an Evidence Based Approach to Treat Foot Ulcers. oResults: 10 non-healing diabetic foot ulcers (DFUs) and 3 pressure ulcers were treated with EpiFix®. 75% of the ulcers healed with EpiFix® at an average healing time of 11.7 weeks after 3.5 applications. Complete healing occurred in 67% of the DFUs and 100% of pressure ulcers. Of the 3 DFUs not healing 100%, 2 were non-compliant and one had foot deformity issues prior to the study causing discontinuation of the graft. oConclusion: Multiple advantages were noted in using EpiFix® to treat non-healing wounds in the VA clinic setting including ease of use and availability of multiple graft sizes to minimize waste. With adequate wound debridement and proper wound bed maintenance, a 75% healing rate of non-healing foot ulcers was achieved with the utilization of EpiFix®. oDehydrated Human Amnion/Chorion Membrane for the Treatment of Full-Thickness Plantar Burn in a Diabetic Patient: A Case Report. oResults: Rapid healing of wound occurred with epithelialization essentially complete 4 weeks after dHACM application. oConclusion: This case report demonstrated that dHACM can be used as an effective treatment for plantar burns in diabetics and deserves further study. oTreatment of Lower Extremity Chronic Wounds with Dehydrated Human Amnion/Chorion Membrane (dHACM): A Vascular Compromised Cohort (ABI<.65). oResults: Patients with wound chronicity and an abnormally low ankle-brachial index (low blood flow to the limbs) were treated with standard wound treatment prior to initiation of dHACM therapy. Wounds were healed with an average weeks to closure of 7.42 and an average of 4.4 applications. oConclusion: dHACM is an extremely efficacious and cost effective alternative in patients failing to achieve appropriate wound area reduction in a timely manner. In this subset of patients, when compared to the previously utilized advanced wound care modalities, a 75% cost savings was realized. oDehydrated Human Amnion/Chorion Membrane Allograft for the Treatment of a Post Surgical Amputation Wound in a Diabetic Patient. oResults: Following sharp debridement period of August 13^th through September 2^nd to prepare wound for advanced wound healing therapy with EpiFix®, advanced wound healing with EpiFix® started on September 3^rd and patient healed on October 15^th. oConclusion: Post-surgical patients need aggressive antibiotic treatment for an extended period of time. Aggressive chemical and sharp debridement is necessary to prepare wound bed. Speed to closure, cost effectiveness of multiple sizes and ease of use are positive attributes for EpiFix®. oExperience with dHACM for a Complicated Sternal and Abdominal Wound. oResults: A total of 6 applications were used over 10 week period; patient presented in week 12 with full closure and wound has continued to be resolved to date. oConclusion: dHACM is a very effective treatment for complicated sternal and abdominal wounds as well as lower extremity ulcerations. Parker H. "Pete" Petit, Chairman and CEO, said, "The independent study abstracts presented at Desert Foot are further indications of the clinical and cost effectiveness of our dHACM allografts. When a graft achieves wound closure with these metrics, we believe we are best serving the clinical and economic needs of our market. We continue to champion the cause of reducing costs of wound closure, and these abstracts highlight those goals." Bill Taylor, President and COO, stated, "In the collective body of work forming the basis for the seven MiMedx poster abstracts, the EpiFix® data involved the treatment of 55 patients. In the combined studies, an average number of 3.5 EpiFix® applications were applied to achieve healed ulcers, and the average number of weeks to achieve healing using the MiMedx allografts was 6.8 weeks. These results mirror the impressive results our dHACM allografts have achieved in prior Randomized Controlled Trials, cross over trials and follow-up studies. " About MiMedx MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 200,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Safe Harbor Statement This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the clinical and cost effectiveness of EpiFix® and AmnioFix®. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include the potential that EpiFix® and AmnioFix® will not perform as expected or will not gain acceptance in the medical community, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012, and the Company's most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws. SOURCE MiMedx Group Contact: Michael Senken, (770) 651-9100
Seven Poster Abstracts Highlight MiMedx Allografts at the 10th Annual Desert Foot Conference
Press spacebar to pause and continue. Press esc to stop.